- ACE 1831 showed superior in vitro and in vivo potency against B cell lymphoma. No significant toxicity of ACE1831-treated mice was observed.
- ACE 1831 represents a novel off-the-shelf treatment for B cell malignancies with potency, cost efficiency and safety advantage.
ALAMEDA, Calif., and TAIPEI, Taiwan, April 8, 2022 -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced that it presented preclinical data on ACE1831, a gamma delta T cell therapy being developed as a treatment for non-Hodgkin’s lymphoma in a digital poster session at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 8-13, 2022 in New Orleans, Louisiana (USA).
Through Acepodia’s unique ACC platform, which links tumor-targeting antibodies to a variety of effector cells, ACE1831 is comprised of gamma-delta T cells armed with an anti-CD20 antibody, enabling it to target cancer cells and overcome tumor defenses to deliver a potent, cancer-killing cellular payload. Details on the on-demand digital presentation can be found below:
Presentation details
Title: ACE1831: A novel allogeneicαCD-20-conjugated Vδ2 gamma delta T product for non-Hodgkin’s Lymphoma
Abstract number: 2617
Date: April 08, 2022 at 1:00 p.m. EDT
” Gamma-delta T cells are known to recognize a broad range of antigens with capability to activate other immune cells in order to attack target cells directly or indirectly and have become a promising cell source in allogeneic application with efficient cytotoxicity against tumor cells with minimal safety concerns. Acepodia’s unique gamma-delta T cells are manufactured from peripheral blood mononuclear cells (PBMCs) collected from healthy donors. When combined with Acepodia’s ACC technology, the company is able to further armor these specific immune effector cells to potentially eradicate tumors and overcome tumor inhibition signals without the use of gene-editing,” said Sonny Hsiao, Ph.D., chief executive officer and co-founder of Acepodia. “We plan to continue developing novel off-the-shelf cell therapy that leverage our unique ACC technology platform, which can be applied to a variety of immune effector cells, and we look forward to advancing our ACE1831 product with the U.S. Food and Drug Administration in the coming months.”
Presentation highlights
The poster presentation will highlight preclinical data on Acepodia’s novel allogeneic gamma delta T cell therapy developed using Acepodia’s proprietary ACC technology for the treatment of non-Hodgkin’s lymphoma.
Key findings from the presentation include:
- The cell manufacturing process of ACE 1831 is consistent, scalable, and reproducible. Two orders of magnitudes cost lower than current autologous CAR-T products. The antibodies used in one dose of ACE 1831 is ~1/1000 of a clinical dose of soluble antibody delivered systemically.
- ACE 1831 showed favorable characteristics with activation receptors and low level of inhibitory markers. CD20-specific binding capacity and cytotoxicity of ACE1831 are well-preserved after cryopreservation.
- Favorable cytokine profile secreted by ACE1831 when encouraging target cells indicates the potency of ACE1831 against B cell lymphoma with low safety concerns.
- ACE 1831 and Obinutuzumab combination provides additional potency against CD20-expressing cancer cells.
- ACE 1831 showed superior in vitro and in vivo potency against B cell lymphoma. No significant toxicity of ACE1831-treated mice was observed.
- In conclusion, ACE 1831 represents a novel off-the-shelf treatment for B cell malignancies with potency, cost efficiency and safety advantage.
About Gamma-Delta T Cells
Acepodia’s gamma delta T cell program harnesses the unique properties of gamma delta T cells to develop a new class of off-the-shelf cell therapies for the treatment of cancer. Gamma delta T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. This cell type can recognize and attack cancerous cells as well as coordinate a broad antitumor immune response by recruiting other immune factors and cells to the site of disease. Gamma delta T cells have also been shown to preferentially traffic to distinct tissues and could be ideally suited for more targeted treatment of certain types of cancers.
About Acepodia
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as gamma delta T cells and off-the-shelf natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring innovative, effective and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit
https://www.acepodia.com and follow Acepodia on
Twitter and
LinkedIn.
